Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs that Modulate Farnesoid X Receptor
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs that Modulate Farnesoid X Receptor
Authors
Keywords
-
Journal
Scientific Reports
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-09-26
DOI
10.1038/srep06437
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: Insights into the antagonism of the hypolipidemic agent Z-guggulsterone
- (2014) Liping Yang et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular Complications
- (2014) Lars Sjöström et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- FXR is a molecular target for the effects of vertical sleeve gastrectomy
- (2014) Karen K. Ryan et al. NATURE
- Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway
- (2014) Ruili Huang et al. Scientific Reports
- Role of Bile Acids in Liver Injury and Regeneration following Acetaminophen Overdose
- (2013) Bharat Bhushan et al. AMERICAN JOURNAL OF PATHOLOGY
- Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery
- (2013) Donna D. Yu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The Tox21 robotic platform for the assessment of environmental chemicals – from vision to reality
- (2013) Matias S. Attene-Ramos et al. DRUG DISCOVERY TODAY
- Improving the Human Hazard Characterization of Chemicals: A Tox21 Update
- (2013) Raymond R. Tice et al. ENVIRONMENTAL HEALTH PERSPECTIVES
- Bile acid receptors as targets for drug development
- (2013) Frank G. Schaap et al. Nature Reviews Gastroenterology & Hepatology
- Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
- (2013) Fei Li et al. Nature Communications
- The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism
- (2013) Lihua Jin et al. Nature Communications
- Acute Human Toxicity of Macrocyclic Lactones
- (2012) Chen-Chang Yang CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators
- (2012) Daniel Merk et al. Future Medicinal Chemistry
- Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
- (2012) Geoffrey Porez et al. JOURNAL OF LIPID RESEARCH
- Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis
- (2012) Barbara Renga et al. PLoS One
- Anti-platelet therapy: phosphodiesterase inhibitors
- (2011) Paolo Gresele et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
- (2011) M. S. Darshan et al. CANCER RESEARCH
- Chemical Genomics Profiling of Environmental Chemical Modulation of Human Nuclear Receptors
- (2011) Ruili Huang et al. ENVIRONMENTAL HEALTH PERSPECTIVES
- Levosimendan: Molecular mechanisms and clinical implications
- (2011) Zoltán Papp et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics
- (2011) R. Huang et al. Science Translational Medicine
- IGF-1 receptor inhibition by picropodophyllin in medulloblastoma
- (2010) Sachiko Ohshima-Hosoyama et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes
- (2010) Hans G.F. Richter et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine
- (2010) Krishnan Rathinasamy et al. BMC CANCER
- Abnormal glucose regulation in pyrethroid pesticide factory workers
- (2010) Jinsong Wang et al. CHEMOSPHERE
- Identification of Clinically Used Drugs That Activate Pregnane X Receptors
- (2010) S. J. Shukla et al. DRUG METABOLISM AND DISPOSITION
- Activation of the Farnesoid X Receptor Provides Protection against Acetaminophen-Induced Hepatic Toxicity
- (2010) Florence Ying Lee et al. MOLECULAR ENDOCRINOLOGY
- Beta tubulin affects the aryl hydrocarbon receptor function via an Arnt-mediated mechanism
- (2009) Tianmin Zhang et al. BIOCHEMICAL PHARMACOLOGY
- Association of Estrogen Receptor and Histone Deacetylase 6 Causes Rapid Deacetylation of Tubulin in Breast Cancer Cells
- (2009) K. Azuma et al. CANCER RESEARCH
- Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)
- (2009) Brenton Flatt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes)
- (2009) Deanna L. Howarth et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders
- (2009) Stefano Fiorucci et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- FXR: a metabolic regulator and cell protector
- (2008) Yan-Dong Wang et al. CELL RESEARCH
- Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy
- (2008) Xiangbin Xing et al. HEPATOLOGY
- Dose- and Route-Dependent Teratogenicity, Toxicity, and Pharmacokinetic Profiles of the Hedgehog Signaling Antagonist Cyclopamine in the Mouse
- (2008) Robert J. Lipinski et al. TOXICOLOGICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More